Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9394MR)

This product GTTS-WQ9394MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9394MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3512MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ6260MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ13452MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ3615MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ938MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ708MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ11925MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ1626MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW